Vera Therapeutics (VERA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vera Therapeutics (VERA)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Key Insights
Critical company metrics and information
Share Price
$48.46Market Cap
$3.07 BillionTotal Outstanding Shares
63.32 Million SharesTotal Employees
82Dividend
No dividendIPO Date
May 14, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.veratx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $185000.00 |
| Net Cash Flow | $185000.00 |
| Net Cash Flow From Financing Activities, Continuing | $305.55 Million |
| Net Cash Flow From Operating Activities | $-120.64 Million |
| Net Cash Flow From Investing Activities | $-185.09 Million |
| Net Cash Flow From Investing Activities, Continuing | $-185.09 Million |
| Net Cash Flow From Operating Activities, Continuing | $-120.64 Million |
| Net Cash Flow From Financing Activities | $305.55 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Research and Development | $113.61 Million |
| Operating Expenses | $145.28 Million |
| Income/Loss From Continuing Operations Before Tax | $-134.38 Million |
| Revenues | $0.00 |
| Income/Loss From Continuing Operations After Tax | $-134.38 Million |
| Nonoperating Income/Loss | $10.91 Million |
| Diluted Average Shares | $54.12 Million |
| Basic Average Shares | $54.12 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss | $-134.38 Million |
| Other Operating Expenses | $31.67 Million |
| Basic Earnings Per Share | $2.61 |
| Diluted Earnings Per Share | $2.61 |
| Net Income/Loss Available To Common Stockholders, Basic | $-134.38 Million |
| Net Income/Loss Attributable To Parent | $-134.38 Million |
| Operating Income/Loss | $-145.28 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Assets | $364.13 Million |
| Equity | $289.06 Million |
| Fixed Assets | $368000.00 |
| Other Non-current Assets | $4.06 Million |
| Noncurrent Assets | $4.43 Million |
| Current Liabilities | $26.46 Million |
| Other Current Liabilities | $18.22 Million |
| Wages | $3.64 Million |
| Accounts Payable | $4.60 Million |
| Noncurrent Liabilities | $53.04 Million |
| Long-term Debt | $50.47 Million |
| Liabilities | $79.50 Million |
| Liabilities And Equity | $368.56 Million |
| Assets | $368.56 Million |
| Equity Attributable To Parent | $289.06 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Other Non-current Liabilities | $2.57 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.